{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T10:13:49Z","timestamp":1695982429951},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,12,17]],"date-time":"2002-12-17T00:00:00Z","timestamp":1040083200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Ophthalmologica Scandinavica"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To evaluate the ocular hypotensive effect of dorzolamide 2% in primary open\u2010angle glaucoma (POAG) patients with intraocular pressure (IOP) of at least 22\u2003mmHg despite ongoing twice daily treatment with brimonidine 0.2%.<\/jats:p><jats:p><jats:bold>Patients and Methods:\u2002<\/jats:bold> Nineteen eyes of 19 patients with POAG and IOP \u2265\u200a22\u2003mmHg, on twice daily brimonidine therapy, were included in the study. Intraocular pressure and adverse effects were recorded on days 2, 7, 14 and 30 after adding dorzolamide three times daily to the treatment.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Mean pretreatment IOP was 27.6\u2003\u00b1\u20032.2\u2003mmHg. This decreased to 24.2\u2003\u00b1\u20032.2\u2003mmHg after a mean duration of 23.8\u2003\u00b1\u200312.1\u2003days. After dorzolamide was added to the treatment, mean IOP was 20.8\u2003\u00b1\u20032.3\u2003mmHg on day 2, 19.3\u2003\u00b1\u20032.2\u2003mmHg on day 7, 18.0\u2003\u00b1\u20032.5\u2003mmHg on day 14 and 17.2\u2003\u00b1\u20032.3\u2003mmHg on day 30. The differences between pre\u2010 and post\u2010treatment IOP values were statistically significant (p &lt;\u200a0.0001, <jats:sc>anova<\/jats:sc> test).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Dorzolamide administered three times daily has significant additive ocular hypotensive effect in POAG patients whose IOP is elevated despite ongoing treatment with brimonidine.<\/jats:p>","DOI":"10.1034\/j.1600-0420.2002.800614.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:19:41Z","timestamp":1047352781000},"page":"632-634","source":"Crossref","is-referenced-by-count":2,"title":["The short\u2010term IOP\u2010lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open\u2010angle glaucoma"],"prefix":"10.1111","volume":"80","author":[{"given":"Sitki Samet","family":"Ermis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faruk","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umit Ubeyt","family":"Inan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,3,12]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)91046-6"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(96)82027-3"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050003"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(05)80042-6"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199708000-00010"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80026-9"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32295-4"},{"key":"e_1_2_5_9_1","first-page":"61","article-title":"Topical eye preparations: optimum use","volume":"36","author":"McKellan K","year":"1995","journal-title":"Curr Ther"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(96)82029-7"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(93)90013-W"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2000.16.251"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00381-0"},{"key":"e_1_2_5_14_1","first-page":"65","article-title":"Alpha\u20102\u2010adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration","volume":"40","author":"Yoles E","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Acta Ophthalmologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0420.2002.800614.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0420.2002.800614.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0420.2002.800614.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T06:10:38Z","timestamp":1695881438000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0420.2002.800614.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1034\/j.1600-0420.2002.800614.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0420.2002.800614.x","archive":["Portico"],"relation":{},"ISSN":["1395-3907","1600-0420"],"issn-type":[{"value":"1395-3907","type":"print"},{"value":"1600-0420","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}